FDA Issues Draft Guidance on Potency Assessment for Active Immunotherapy Products

What this means for your practice

For healthcare businesses, particularly those engaged in the development, administration, or future consideration of advanced therapies such as immunotherapies, cellular therapies, or gene therapies, this draft guidance signifies the FDA's continued focus on the robust scientific assessment of product quality and efficacy. While direct impact may be limited for traditional telehealth, medspas, dental, or chiropractic practices, it underscores the stringent regulatory environment governing innovative biological products. Practices involved in, or partnering with entities developing, new therapeutic agents should understand that the FDA prioritizes methods for ensuring product potency, which is crucial for patient safety and treatment effectiveness. Maintaining awareness of such guidance is essential for any practice considering expansion into or offering services related to advanced medical interventions, as regulatory expectations for product characterization and quality control are consistently high.

Rockville, MD – The U.S. Food and Drug Administration (FDA) has announced the availability of a new draft guidance document titled “Potency Assessment of Active Immunotherapy Products.” This important document provides comprehensive recommendations for the development, validation, and evaluation of assays used to assess the potency of active immunotherapy products (ACTIMPs). The release signals the FDA's ongoing commitment to ensuring the quality and efficacy of advanced therapeutic products.

Purpose of the Draft Guidance

The draft guidance aims to outline the FDA’s current thinking on designing, validating, and evaluating potency tests specifically for ACTIMPs. Potency assessment is a critical component of a broader potency assurance strategy, ensuring that these complex biological products consistently deliver their intended therapeutic effects. When finalized, this guidance will serve as a key resource for manufacturers and developers of active immunotherapies.

Scope of Active Immunotherapy Products

The guidance addresses a range of ACTIMPs, clarifying that it is intended to supplement existing regulatory frameworks. Specifically, it builds upon the December 2023 draft guidance for industry, “Potency Assurance for Cellular and Gene Therapy Products.” This new document provides additional advice and considerations tailored to ACTIMPs, including those that are peptide- and protein-based and are not classified as cellular or gene therapy products. This distinction is important, as it covers a broader spectrum of immunological interventions.

Importance of Potency Assays

Potency assays are analytical tests designed to measure the biological activity of a product. For active immunotherapy products, ensuring consistent potency is paramount. These products often involve complex biological mechanisms intended to stimulate or modulate the body's immune system to fight diseases. Inaccurate potency assessments could lead to products that are either ineffective or, in some cases, harmful to patients. Therefore, robust and validated potency tests are crucial for demonstrating product quality, ensuring patient safety, and supporting regulatory approval.

The FDA emphasizes that the recommendations within this draft guidance are designed to assist the industry in establishing scientifically sound methods for potency evaluation throughout the product lifecycle, from early development through commercial manufacturing. This includes considerations for initial product characterization, batch release testing, and stability studies.

Providing Comments to the FDA

The FDA invites stakeholders, including manufacturers, researchers, healthcare providers, and the public, to submit comments on this draft guidance. Comments are vital for the agency to refine the guidance and ensure it is clear, practical, and scientifically sound before its finalization. Submitting comments allows interested parties to contribute to the regulatory landscape governing these innovative therapies.

To ensure that comments are considered by the Agency before it begins work on the final version, electronic or written comments must be submitted by November 18, 2026.

How to Submit Comments:

• Electronic Submissions: Comments can be submitted through the Federal eRulemaking Portal at www.regulations.gov. Follow the instructions for submitting comments, ensuring to reference Docket No. FDA-2026-D-8561.
• Written/Paper Submissions: Mail or hand-deliver written comments to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Two copies should be submitted for confidential information, with one redacted copy for public viewing. All submissions must include Docket No. FDA-2026-D-8561.

All received comments, except for those specifically designated as confidential and submitted as such, will be posted publicly on www.regulations.gov. The FDA encourages all interested parties to review the draft guidance and provide feedback to help shape the final document.

This draft guidance represents another step in the FDA's efforts to establish clear regulatory pathways and expectations for the rapidly evolving field of advanced therapies. Stakeholders are encouraged to engage with this process to ensure that the final guidance effectively supports both innovation and public health.

Key Facts

| Detail | Value | |---|---| | Agency | Food and Drug Administration (FDA), HHS | | Action | Notice of availability of draft guidance | | Docket Number | FDA-2026-D-8561 | | Topic | Potency Assessment of Active Immunotherapy Products | | Comment Deadline | November 18, 2026 | | Purpose | Provides recommendations for developing assays to assess potency for active immunotherapy products (ACTIMPs) |

Frequently Asked Questions

What is the new FDA draft guidance about?

The draft guidance, 'Potency Assessment of Active Immunotherapy Products,' provides recommendations for developing and evaluating assays to assess the potency of active immunotherapy products (ACTIMPs).

What kind of products does this guidance apply to?

It applies to active immunotherapy products (ACTIMPs), including peptide- and protein-based ACTIMPs that are not cellular or gene therapy products, and supplements previous guidance on cellular and gene therapy products.

What is the goal of this guidance?

When finalized, this guidance will describe the FDA's current thinking regarding the design, validation, and evaluation of potency tests for ACTIMPs as part of a potency assurance strategy.

How does this guidance relate to other FDA guidance documents?

This guidance is intended to supplement the December 2023 draft guidance for industry, when finalized, on 'Potency Assurance for Cellular and Gene Therapy Products,' with specific advice for ACTIMPs.

How can I submit comments on this draft guidance?

You can submit electronic comments via www.regulations.gov or send written/paper submissions to the Dockets Management Staff (HFA-305), Food and Drug Administration, by November 18, 2026, referencing Docket No. FDA-2026-D-8561.

Source: FDA — Notice: Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability · 2026-08-20